8-KLeadership ChangesExhibits & Filings

IDEXX LABORATORIES INC /DE 8-K Report, Executive Changes (Nov 12, 2020)

Filed November 12, 2020For Securities:IDXX

Summary

IDEXX Laboratories, Inc. (IDXX) announced the election of Dr. Asha S. Collins as an independent Class I Director to its Board of Directors, effective November 11, 2020. This appointment increases the Board size from ten to eleven directors and adds Dr. Collins to the Nominating and Governance Committee. This move signals a commitment to strengthening board oversight and governance with diverse expertise. Investors should note that Dr. Collins has no related party transactions and will receive standard compensation for non-employee directors, prorated for her partial year service. The company also furnished a press release detailing this appointment, which is attached as an exhibit. This proactive board expansion is a positive development, indicating the company's focus on strategic growth and robust corporate governance. Investors can look forward to Dr. Collins's contributions, particularly in the areas of nominations and governance, as she is expected to stand for election by stockholders at the 2021 annual meeting.

Key Highlights

  • 1IDEXX Laboratories appointed Dr. Asha S. Collins as an independent Class I Director, effective November 11, 2020.
  • 2The Board of Directors was expanded from ten to eleven members to accommodate the new director.
  • 3Dr. Collins has been appointed to the Nominating and Governance Committee.
  • 4There are no disclosed related person transactions involving Dr. Collins.
  • 5Dr. Collins will receive compensation consistent with other non-employee directors, prorated for her service period.
  • 6Annual stock grants and options will be prorated for Dr. Collins, commencing December 1, 2020.
  • 7A press release dated November 12, 2020, was issued and filed as an exhibit, announcing the appointment.

Frequently Asked Questions

Dr. Asha S. Collins is an independent Class I Director elected to IDEXX Laboratories' Board of Directors. Her appointment aims to strengthen the board's expertise and governance, particularly within the Nominating and Governance Committee. She brings valuable experience to the company's oversight.

Dr. Collins's election increases the size of the Board of Directors from ten to eleven members. She has been designated as a Class I Director and appointed to the Nominating and Governance Committee.

Dr. Collins will receive the same compensation as other non-employee directors, which includes prorated cash fees for her service in the fourth quarter of 2020. She will also receive prorated annual deferred stock unit and stock option grants on December 1, 2020, reflecting her service period until the 2021 annual meeting.

Based on the filing, there are no related person transactions or proposed related person transactions with Dr. Collins that need to be reported under SEC regulations.